Evidence map›Paper›PMID 38977473›Full record

ArticleEuropean archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery2024

Severely complicated ear infection in a patient treated with ixekizumab: a case report.

Léonore Maertens, Naomi Pollet, Marta Clarysse, Lore Vanderbeke, Nicolas Verhaert, Christian Desloovere, Elke Loos

Abstract readCase Reports
PubMed Publisher
In one paragraph

Article in European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Léonore MaertensDepartment of Otorhinolaryngology-Head and Neck Surgery, ENT Resident, University Hospitals Leuven, Leuven, 3000, Belgium. leonore.maertens@gmail.com.ORCID http://orcid.org/0009-0005-2741-8567
Naomi PolletDepartment of Otorhinolaryngology-Head and Neck Surgery, ENT Resident, University Hospitals Leuven, Leuven, 3000, Belgium.ORCID http://orcid.org/0000-0002-1252-2856
Marta ClarysseDepartment of Otorhinolaryngology-Head and Neck Surgery, ENT Resident, University Hospitals Leuven, Leuven, 3000, Belgium.ORCID http://orcid.org/0009-0001-8956-400X
Lore VanderbekeInternal Medicine Department, University Hospitals Leuven, Leuven, 3000, Belgium.ORCID http://orcid.org/0000-0002-3364-1213
Nicolas VerhaertDepartment of Otorhinolaryngology-Head and Neck Surgery, ENT Resident, University Hospitals Leuven, Leuven, 3000, Belgium.ORCID http://orcid.org/0000-0002-3512-1334
Christian DesloovereDepartment of Otorhinolaryngology-Head and Neck Surgery, ENT Resident, University Hospitals Leuven, Leuven, 3000, Belgium.ORCID http://orcid.org/0000-0001-9766-8610
Elke LoosDepartment of Otorhinolaryngology-Head and Neck Surgery, ENT Resident, University Hospitals Leuven, Leuven, 3000, Belgium.ORCID http://orcid.org/0000-0002-5479-0461

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

We report a case of a severe ear infection in a 35-year-old man treated with ixekizumab for psoriasis. Ixekizumab is a humanized monoclonal antibody that selectively prevents the interaction between interleukin 17 A and its receptor. Biologicals like ixekizumab are used to achieve symptom relief in autoimmune diseases including psoriasis. Unlike the mild upper respiratory tract infections usually described as side-effects of this treatment, we report a case of a patient who presented with a severe otitis media, complicated with a facial paresis and nasopharyngeal abscess. To the best of our knowledge, this is the first case presenting a severe, complicated ear infection as a possible side effect of ixekizumab. We conclude that when using ixekizumab, vigilance for upper airway infections is needed and if necessary, interruption of therapy should be considered. However, further research is needed to confirm this hypothesis.

Indexed as

Antibodies, Monoclonal, HumanizedOtitis MediaPsoriasisAbscessAdultDermatologic AgentsHumansMaleAntibodies, Monoclonal, HumanizedDermatologic AgentsixekizumabCase reportFacial nerve palsyIL-17IxekizumabStreptococcus anginosus group

Identifiers

PMID38977473

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.